Sector News

HHS confirms Sharpless to serve as acting FDA chief

March 13, 2019
Life sciences

After FDA commissioner Scott Gottlieb, M.D., abruptly announced his resignation a week ago, the agency has its next acting chief. Ned Sharpless, M.D., currently the director of the National Cancer Institute, is assuming the role.

The Department of Health and Human Services confirmed the move on Twitter Tuesday.

Sharpless has served as NCI director since October 2017, overseeing the United States’ top cancer research organization with an annual budget of nearly $6 billion. Before serving at the institute, he was the University of North Carolina’s Lineberger Comprehensive Cancer Center director since January 2014.

He’ll take the reins from Gottlieb, an FDA commissioner popular among the pharmaceutical industry, who served for nearly two years. While running the agency, Gottlieb made lowering drug costs and spurring pharmaceutical innovation two of his top priorities. During his tenure, approval numbers for generics and new brands soared.

Gottlieb’s quick exit a week ago sparked panic in the biopharma world, as the commissioner had been seen as an ally to the industry, or at minimum a regulator with a deep understanding of biopharma.

In Sharpless, the FDA is getting a “great public health champion” and a “dedicated physician,” Gottlieb tweeted on Tuesday. He added that Sharpless will be “warmly welcomed” at the agency.

By Eric Sagonowsky

Source: FiercePharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.